Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte R with Dextrose 5% is an intravenous solution providing electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) and dextrose. Dextrose provides calories and may prevent ketosis; electrolytes maintain or restore acid-base balance and provide essential ions for cellular function.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
Replacement of extracellular fluid and electrolytes in conditions such as dehydration, hypovolemia, and metabolic acidosis,Maintenance fluid therapy in patients who cannot take oral fluids,Perioperative fluid and electrolyte management
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous infusion at a rate of 125-200 m L/hour (3 m L/kg/hour) for fluid and electrolyte maintenance, adjusted based on clinical status, serum electrolytes, and glucose monitoring.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
Not applicable as a composite solution; glucose half-life ~1.5-2 h in normal individuals, extended in renal impairment; electrolytes follow body homeostasis.
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Dextrose is metabolized via glycolysis and subsequent pathways; electrolytes are excreted or reabsorbed as needed; acetate and gluconate are metabolized to bicarbonate in the liver.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Renal: ~100% as water, electrolytes, and glucose; no biliary or fecal elimination of active drug components.
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
None for water and electrolytes; glucose is not protein bound.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
0.2 L/kg for water; electrolytes distribute according to body compartments (ECF ~0.2 L/kg, ICF ~0.4 L/kg); glucose initial Vd ~0.2 L/kg.
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Intravenous: 100%.
Intravenous: 100% bioavailability.
No specific dose adjustment for GFR; use with caution in renal impairment due to risk of fluid overload and electrolyte disturbances. Monitor serum potassium, phosphate, and magnesium levels closely. In severe renal impairment (GFR <30 m L/min), consider alternative fluids with lower potassium and phosphate content.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
No specific Child-Pugh based adjustment. Use with caution in severe hepatic impairment due to altered metabolism of dextrose and lactate; monitor glucose and lactate levels. Avoid in patients with lactic acidosis or severe hepatic dysfunction.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Intravenous infusion based on body weight: 5-10 m L/kg per dose for maintenance, repeated as needed; typical rate: 100-150 m L/kg/day for fluid maintenance, adjusted for clinical status. Monitor glucose and electrolytes frequently.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Use with caution due to age-related decline in renal function and higher risk of fluid overload. Start at lower infusion rates (100-125 m L/hour) and titrate based on clinical response and monitoring of electrolytes, renal function, and volume status.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
None.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Monitor serum electrolytes, fluid balance, and acid-base status closely,Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload,Avoid rapid infusion or large volumes in patients with reduced renal function,Use with caution in patients with diabetes mellitus due to dextrose content
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Hypernatremia,Hypersensitivity to any component,Severe metabolic alkalosis,Anuria or oliguria (unless due to hypovolemia)
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No specific food interactions with IV administration. However, oral intake should be coordinated with IV therapy to avoid fluid or electrolyte imbalance. In patients with diabetes, adjust oral carbohydrate intake to account for dextrose calories.
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
No known teratogenic risk. Dextrose and electrolytes are physiologic components; no fetal harm reported with standard use. High dextrose concentrations may cause fetal hyperglycemia, particularly in gestational diabetes.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Compatible with breastfeeding. Dextrose and electrolytes are normal milk constituents; no adverse effects expected. M/P ratio not applicable.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
No standard dose adjustment required. Increased plasma volume may necessitate higher fluid load; adjust rate based on clinical status, glucose tolerance, and hemodilution.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
Isolyte R w/ Dextrose 5% is an isotonic, balanced electrolyte solution with 5% dextrose, providing 170 kcal/L. It is contraindicated in patients with lactate metabolism disorders (e.g., severe hepatic failure) due to lactate content. Monitor serum glucose closely in diabetic patients; dextrose may cause hyperglycemia. Do not administer simultaneously with blood through same IV line due to risk of hemolysis. Check for particulate matter and container leaks before use.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
This intravenous solution provides fluids, sugars, and electrolytes to maintain hydration and nutritional balance.,Tell your healthcare provider if you have diabetes, kidney disease, liver disease, or a history of heart failure.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your provider if you feel swelling in your arms or legs, shortness of breath, or rapid weight gain (signs of fluid overload).,Blood sugar and electrolyte levels will be monitored regularly during treatment.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte R with Dextrose 5% is an intravenous solution providing electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) and dextrose. Dextrose provides calories and may prevent ketosis; electrolytes maintain or restore acid-base balance and provide essential ions for cellular function.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate of 125-200 m L/hour (3 m L/kg/hour) for fluid and electrolyte maintenance, adjusted based on clinical status, serum electrolytes, and glucose monitoring.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No known teratogenic risk. Dextrose and electrolytes are physiologic components; no fetal harm reported with standard use. High dextrose concentrations may cause fetal hyperglycemi. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.